- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Lynparza approved in Japan for 1st-line
AnnouncementREG - AstraZeneca PLC - Breztri Aerosphere (PT010) approved in Japan for
AnnouncementREG - AstraZeneca PLC - Lynparza approved in the EU for 1st-line
AnnouncementREG - AstraZeneca PLC - Calquence significantly prolonged the time patient
AnnouncementREG - AstraZeneca PLC - Publication of a Prospectus
AnnouncementREG - AstraZeneca PLC - Calquence Phase III ELEVATE-TN trial met primary
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Lynparza nearly doubled time patients lived with
AnnouncementREG - AstraZeneca PLC - Pooled analyses of the roxadustat global Phase III
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Trastuzumab deruxtecan demonstrated clinically
AnnouncementREG - AstraZeneca PLC - Calquence PhIII ASCEND trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Qternmet XR approved in the US for type-2 diabetes
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Lynparza receives positive EU CHMP opinion for 1st
AnnouncementREG - AstraZeneca PLC - Result of AGM
Announcement